Mutation rates at a (CA)13 microsatellite in human colon cancer HCT116-A2.1 cells by two different computational methods
| Concentration | Method of the mean | Maximum likelihood | |||
|---|---|---|---|---|---|
| Treatment | Control | Treated (%) | Control | Treated (%) | |
| Cinnamaldehyde | 125 µM | 6.1±1.8 | 6.6±2.4 (108) | 5.2±0.9 | 6.4±1.4 (124) |
| 250 µM | 8.1±3.9 (132) | 5.2±0.9 | 6.0±2.4 (115) | ||
| Taurine | 10 mM | 2.9±0.9 | 3.5±1.0 (120) | 2.8±0.5 | 3.1±0.5 (111) |
| 15 mM | 4.5±1.3 (154) | 2.8±0.5 | 2.7±0.5 (98) | ||
| Thymoquinone | 1.25 µM | 6.3±1.8 | 5.2±1.6 (82) | 5.4±0.9 | 4.8±0.8 (89) |
| 2.50 µM | 3.0±1.0* (47) | 5.4±0.9 | 2.5±0.5* (46) | ||
| Mesalazine† | 5 mM | 6.0±1.1 | 4.9±1.4* (82) | 4.8±1.1 | 4.4±2.1 (92) |
Note: data (×10−4) are mean±SE of mutation rates per microsatellite per generation.
Changes are indicated in (%) treated versus control.
*p<0.05.
†Data from reference.22